‘Kanarb’ shows off in front of circulatory system experts around the world

A Korean new drug Kanarb in the hypertension market is challenging to the global market beyond the Korean market. The drug is expected to be called the first Korean global drug recognized by both of the Korean and foreign industries. While it is currently recording KRW 40 billion sales annually, the company has a goal to raise its sales to KRW 200-300 billion. Moreover, after its long-term R&D,...